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Abstract Perinatal Asphyxia—oxygen deficit at delivery—
can lead to severe hypoxic ischaemic organ damage in
newborns followed by a fatal outcome or severe life-long
pathologies. The severe insults often cause neurodegenerative
diseases, mental retardation and epilepsies. The mild insults
lead to so-called “minimal brain-damage disorders” such as
attention deficits and hyperactivity, but can also be associated
with the development of schizophrenia and life-long func-
tional psychotic syndromes. Asphyxia followed by re-
oxygenation can potentially lead to development of several
neurodegenerative pathologies, diabetes type 2 and cancer.
The task of individual prediction, targeted prevention and
personalised treatments before a manifestation of the life-long
chronic pathologies usually developed by newborns with
asphyxic deficits, should be given the extraordinary priority in
neonatology and paediatrics. Socio-economical impacts of
educational measures and advanced strategies in development
of robust diagnostic approaches targeted at effected molecular
pathways, biomarker-candidates and potential drug-targets for
tailored treatments are reviewed in the paper.
Keywords Paediatrics . CNS injury. Neurodegeneration .
Diabetes . Cancer. Personalised medicine
Introduction
Asphyxia—insufficient oxygen supply—can lead to severe
hypoxic ischaemic organ damage in newborns followed by
a fatal outcome or severe life-long pathologies. Although
birth asphyxia is not always distinguishable as the cause of
perinatal and postnatal death, its pronounced impact for the
mortality in newborns is well-documented, representing
profound deficits in current healthcare systems worldwide.
Secondary to birth asphyxia, a postnatal manifestation of
hypoxic-ischaemic encephalopathy (HIE) is frequently
observed being associated with either mild or severe organ
damage in asphyxiated newborns, both leading to the
development of chronic pathologies. The severe insults
often cause neurodegenerative diseases, mental retardation
and epilepsies. The mild insults lead to so-called “minimal
brain-damage disorders” such as attention deficits and
hyperactivity, but can also be associated with the develop-
ment of schizophrenia and life-long functional psychotic
syndromes. In some particular cases it is difficult to
discriminate between mild and severe asphyxia: advanced
methodology to improved diagnosis of birth asphyxia and
prediction of individual short- and long-term outcomes
obligatory needs to be developed. The task of individual
prediction (Fig. 1), targeted prevention and personalised
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treatments before a manifestation of life-long chronic
pathologies usually developed by asphyxiated newborns,
should be given the extraordinary priority in paediatrics.
Global burden in newborn healthcare and the role
of perinatal complications
According to the statistical data collected in years 2000–
2002 by the Global Burden of Disease Study, worldwide 56
million deaths occur every year, from that 10.5 million, i.e.
20% represent children aged below 5 years. In this group,
the leading cause of death is perinatal complications [2].
Current statistical data considering epidemiology of prena-
tal, perinatal and postnatal pathologies are worldwide have
not been systematically analysed; sometimes these data are
even controversial as provided for single countries. Here we
overview the most systematic studies as published to the
issue. One the most reliable issue-related studies performed
in the USA has demonstrated the perinatal morbidity
comprising 60% of the child death cases giving a general
idea of the biggest impact of perinatal complications in
childhood [3] and reflecting extensive issue-related prob-
lems in corresponding healthcare system as well as massive
deficits in knowledge about and/or practical application of
targeted prevention and effective treatment of neonatal,
perinatal and postnatal pathologies.
Particularly alarming statistical data are currently delivered
by developing countries with large populations. Currently
one-third part of all neonatal deaths registered worldwide
occurs in India [4, 5]. The most frequent prenatal, perinatal
and neonatal complications leading to death are summarised
in Fig. 2 for Tamil Nadu—one of the Indian regions.
It is obvious that the number of deaths during the first week
of life comprises the highest overall mortality in newborns.
Consequently, in Tamil Nadu, 81.5% of deaths were moni-
tored during the first week of life, compared to more than 4-
times (18.5%) and 10-times (8.2%) lower mortality during the
second week and after the sixth month of life, respectively [6].
Further studies performed in South Africa have demon-
strated clear area-dependent preferences in distribution of
neonatal death rates (Fig. 3). There is an obvious inverse
relationship between a decreased density of healthcare units
and an increased mortality in newborns.
Intensity of medical care has great impacts on neonatal
death rates even in countries, where a healthcare is
generally well established. Hence, despite of the overall
low mortality of newborns in Canada, an increased risk of
stillbirth and neonatal death during weekends is well
documented indicating significant fluctuations in the inten-
sity, i.e. quality of healthcare, the level of which, therefore,
depends of the day of a week [8].
Currently a categorisation of perinatal complications is
still not well classified. Worldwide there are three actively
used diagnostic systems, namely Nordic-Baltic, Aberdeen
and Wigglesworth one [9]. Among perinatal complications,
40% of all cases are defined as “unknown”, when
diagnosed according to the parameters of the Aberdeen
classification system alone. The Wigglesworth system
Fig. 1 Newborn with asphyxic deficits. For timely protection against
severe outcomes, a predictive diagnostics should be performed to
detect individual pathology predisposition followed by targeted
preventive measures and creation of personalised treatment algo-
rithms. Data taken from [1]
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Fig. 2 Frequent complications leading to neonatal deaths with the
highest contributions by birth asphyxia as monitored Tamil Nadu,
India. Data taken from [1, 6]
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Fig. 3 Prevalence of neonatal mortality represented in percentages
with respect to a delivery area as monitored in South Africa [7]
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provides satisfactory diagnosis for less then 60% of cases.
Although in average 85% of the cases can be reliably
diagnosed by a combination of all three diagnostic systems,
still 15% of the cases remain undiagnosed [9]. Therefore, we
conclude the absolute necessity to optimise currently used
diagnostic systems by utilising innovative non-invasive
technologies and creating reliable approaches capable to
provide information for follow-up personalised treatments.
Prevalence and risk factors of birth asphyxia
Among different countries, a prevalence of birth asphyxia
varies dramatically depending on corresponding geographic
localisation and socio-economical level of development
(Fig. 4).
The data are well in agreement with the above given
conclusions about a direct influence of the healthcare
quality on delivery outcomes.
Hypoxic ischaemic organ damage can occur at ante-
partum—prenatal asphyxia, at intrapartum—perinatal
(birth) asphyxia, or after delivery as postpartum asphyxia.
Acute maternal infections, pre-maturity of a newborn and
multiple births are the most frequent natural risk factors
leading to hypoxic conditions in a fetus or newborn [8].
However, specifically perinatal asphyxia (PA) occurring at
the parturition process of delivery is the leading cause of
the overall mortality due to hypoxic-ischaemic damage to
newborns. Consequently, the quality of a medical care at
birth is crucial for the overall newborn mortality and long-
term outcomes. The impact of a density of healthcare units
is even more pronounced in prevalence of PA-related
mortality (Fig. 5) compared to this of general mortality in
newborns (Fig. 3).
Ethical and socio-economical impacts of educational
measures in prevention of birth asphyxia
Current limited perinatal and postnatal diagnostics cause
long-term consequences in a society, which can include a
spectrum of negative aspects. From a social and ethical
point of view, innovative technologies for an early/
predictive diagnostics and individualised treatment should
be applied in all routine medical services. From an
economic point of view, emphasis should be put into the
costs effectiveness to promote advanced healthcare with
appropriate budgets for targeted prevention applied before
pathologies manifest.
What are the potential measures that can be applied
already now? One example of the high impact of
educational measures to improve the healthcare system is
given in Figs. 6 and 7.
The prevalence of birth asphyxia registered for children
born to educated mothers is several times lower compared
with those born to uneducated/illiterate mothers. It is
evident that strong restrictions in the amount of education
lead to dramatic deficits and costs that are essentially then
felt in other branches of the system, including a conse-
quently chaotic healthcare in the society. When the whole
spectrum of asphyxia-related pathologies is considered such
as type 2 diabetes, neurodegenerative diseases and cancer,
the consequent costs increase dramatically for treatment of
manifesting pathologies. Therefore, new guidelines are
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Fig. 4 The prevalence of birth
asphyxia as documented by a
series of population studies: a
corresponding number of cases
has been calculated per 1,000 life
births. Data taken from [10–21]
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essential to regulate the field in favour of educational
measures, personalised treatment approaches before mani-
festing pathologies, particular emphases on primary pre-
vention, innovative reimbursement programmes introduced
by policy-makers [22].
Grading of perinatal asphyxia
Depending on the grade of oxygen deficiency that a newborn
suffered at delivery and individual reactions developed under
asphyxic event, the corresponding perinatal asphyxia is
graduated either as mild or severe one. The latter is the most
frequent cause of perinatal and neonatal death as well as of
severe injury of central nervous system (CNS) and damage to
other organs resulting in hypoxic-ischaemic encephalopathy,
nephropathy, and cardiomyopathy as the most usual long-term
outcomes. The APGAR score is named by the author, Dr.
Virginia Apgar, who has developed the system in the middle
of 20th century [24]. Since that time, it is still the worldwide
practised grading of the severity of perinatal asphyxia, as
summarised in Fig. 8.
The Apgar score uses five criteria: Appearance, Pulse,
Grimace, Activity, and Respiration, shortly APGAR.
Ranging from zero to ten, the scores below 3 are considered
as critically low for cases of the highest emergency, 4 to 6
—as fairly low, and the scores equal to or above 7
correspond to generally normal states of the newborn’s
health. In regions with a traditionally high neonatal
mortality, the Apgar score is frequently calculated as less
than seven. Hence, in Saudi Arabia, the Apgar scores below
7 were registered for 22% of newborns; 7.6% of them
represented cases of neonatal morbidity [19]. In Tanzania,
Apgar scores below 7 for registered for 79% of the neonatal
deaths [21]. These are clear indications for perinatal
asphyxia as the major cause of neonatal morbidity.
The APGAR grading of a severity of perinatal asphyxia
is relevant for the most probable short-term outcomes, such
as generalised survival potential and an immediate risk of
severe damage to CNS after asphyxic event. However, this
diagnostic system has not been designed for prognostic
purposes, evaluation of long-term risks and individual
outcomes. Adequate diagnostic systems are currently
missing and obligatory must be created to predict and
prognose long-term risks and individual outcomes for
asphyxiated newborns. In particular, a reliable diagnostic
and prognostic system should be further created for
newborns suffered from mild asphyxia graded as fairly to
slightly low APGAR scores. Long-term affects of mild
asphyxia are completely underestimated, due to less
dramatic short-term outcome compared to severe asphyxia.
Although mild insults do not cause perinatal death, the most
frequent long-term outcomes include functional psychotic
syndromes, attention deficit disorder, hyperactivity, epilep-
sies, schizophrenia and plenty of other chronic/life-long
pathologies, which are assumed to be potentially caused by
a sub-optimal delivery. The reaction towards mild insults is
highly individual and should be subjected to extensive pre/
clinical studies, in order to promote optimal protective
measures and possibly full recovery.
Moving from basic research to clinical implementation:
essential steps in creating the robust diagnostic platform
for personalised treatment of newborns with asphyxic
deficits
The overall concept foresees advanced strategies as summar-
ised in Fig. 9. An optimal set-up of stakeholders and a high
quality of the performance of single operating steps (sub-
projects) guarantee for a discovery and qualification of
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innovative diagnostic approaches and valid drug targets to be
successfully implemented in clinical practice. The crucial
step in the overall experimental scheme is a well-established
animal model to simulate clinical conditions. In the case of
perinatal asphyxia, these are robust experimental conditions
for totally-reproducible birth asphyxia and reliable (neuro)
physiological tests characterising the specific features of the
pathology. The animal model that has been created to simulate
the perinatal asphyxia with characteristic asphyxia-related
long-term outcomes in humans is described below. Optimal
experimental conditions and general regulations including
ethical aspects for a successful bio-preservation and bio-
banking will be separately discussed in current and follow-up
journal-issues.
In vivo simulation of human birth asphyxia
A reliable animal model of perinatal asphyxia has been
established by M. Herrera-Marschitz et al. [25]. This
model provides highly reproducible results and is well-
acknowledged worldwide. The most important steps are
illustrated in Fig. 10.
Pregnant Wistar rats at the last day of gestation are neck-
dislocated and quickly hysterectomised. The uterus horns
containing fetuses are placed in a water-bath at 37°C for
time-periods ranging 0–20 min, in order to simulate the in
vivo mild (below 10 min) and severe (above 15 min) birth
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Fig. 8 A brief description of the
APGAR system for the severity
grading of perinatal asphyxia (PA)
in newborns: PA severity ranges
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score 2 for all five parameters
evaluated; *acrocyanosis occurs
due to altered parameters of blood
flow resulting in a gradually
changing skin colour. Data taken
from [1, 24]
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asphyxia. Following asphyxiation, the uterus horns are
rapidly opened, and the pups are removed and stimulated
for breathing (re-oxygenation period). In vivo and in vitro
neurophysiological evaluations are performed in order to
characterise the severity grade of asphyxia and brain injury
[26]. The long-term CNS effects of the simulated asphyxia
are examined by behavioural evaluations. Ex vivo and in
vitro analyses characterise the consequent damage to
several organ, pathology-specific alterations in (sub)cellular
structures and condition specific molecular patterns.
Behavioural tests applied to confirm clinically relevant
alterations in asphyxiated rats
Adult rats subjected to perinatal asphyxia as described
above, are tested for long-term modifications in non-
spatial and spatial memory, and in motor tasks. They
display impaired novel object recognition in accordance
with the rodent model used to assess non-spatial working
memory deficits [27, 28]. In contrast, the Y maze or
Barnes, maze tests validated for spatial memory deficits,
do not demonstrate any effects by the asphyxiation
episodes, at delivery [28–30]. An evident impairment in
motor coordination is monitored by rotarod performance;
however, no significant difference in intensity of non-
finalised motor behaviour and time-course of gross motor
activity can be observed between the asphyxiated and
control rats [28]. Taken together, the experimental rates
exposed to the birth asphyxia, evidently, demonstrate
altered fine movement functions, reflecting deficits in
motor coordination and balance, whereas the locomotion
and general motor activity remained non-affected. The
cognitive and motor deficits observed in rats indicate the
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Fig. 9 Advanced strategies in the development of a robust diagnostic platform and novel drug targets with high potential for their clinical
implementation
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Fig. 10 The sequence of steps
resulting in a set-up of clinically
relevant perinatal asphyxia con-
ditions and well reproducible
asphyxiated newborn rats [25].
The uterus horns containing
foetuses are placed in a water-
bath at 37°C for 20 min to
simulate severe birth asphyxia.
Without re-oxygenation, the as-
phyxiated pups die after 22 min.
By using this model, mild
insults can be observed by 5–
10 min simulation of perinatal
asphyxia followed by immediate
re-oxygenation
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deleterious effects of birth asphyxia similar to those
observed in human newborns suffered from perinatal
asphyxia. The above described experimental model allows
for monitoring of the deficits in cognitive performance,
specific asphyxia-induced changes in motoric and stress-
mediated behaviour [31, 32].
Expression profiling by “Gene Hunting”- technology
discovered functional groups of genes involved
in the pathophysiology of perinatal asphyxia
The principles underlie the “gene hunting”-technology of
“subtractive hybridisation”, applied to profile differentially
expressed gene-transcripts, has been described in several
publications [33–35].
This strategy has been chosen to identify functional
groups of genes, differentially regulated in the brain under
the severe birth asphyxia versus normoxia [36–38]. The
transcription profiling revealed the following functional
groups of genes affected by the asphyxia [36]:
– synthesis of signalling molecules (such as nitric-oxide)
and heat-shock proteins
– nuclear and DNA-binding factors
– transcription and translation regulation
– energy metabolism
– membrane transport
– ion-handling
– several metabolic pathways (e.g. nucleic acid, lipid
metabolism)
– redox-control and free-radical production
– proto-oncogenes.
These functional groups comprise the genes, the tran-
scriptional rates of which are significantly altered in brain
of asphyxiated rats. Concomitantly, the same functional
groups have been reported as resulting from research
projects dedicated to the translational alterations identified
by differential protein profiling [39]. These extensive
alterations in the central molecular pathways can be
potentially implicated in the development of potential
asphyxia-related chronic complications, such as several
sorts of degenerative processes in organs and onset of pre/
cancerous lesions in the affected organs as summarised in
Fig. 11.
Central biological processes affected by perinatal
asphyxia
Asphyxia is characterised by hypoxia (mild or severe
oxygen deficiency) and the pH-values reduced below 7.
Depending on the grade of oxygen deficits (see previous
subchapters in the manuscript) perinatal asphyxia causes
either severe brain injury or subtle perturbations affecting
further development of the central nervous system (CNS)
[40–42]. Under global hypoxia, “up-stream” CNS damage
is followed by ischaemic lesions in kidney [43] and heart
[44]. Global hypoxia impairs the general availability of
oxygen [45, 46], affecting the electron transport pathways
[47], increasing calcium influx and triggering fragmentation
of both chrDNA and mtDNA [48]. The consequently
triggered cascade of biochemical events creates a signifi-
cant imbalance in central oxygen-dependent molecular
pathways. Even more damaging is the reversion to normal
oxygen levels during the post-asphyxic re-oxygenation
associated with an extensive production of highly reactive
oxygen species. Respectively, suppression and over-
activation of the affected molecular pathways occur during
both periods: hypoxia and re-oxygenation [36, 38]. Estab-
lished chronic deficits underlie severe pathologies devel-
oped as individual long-term outcomes of perinatal
asphyxia. Among them is the synthesis of compounds
critical for postnatal CNS-development, nerve growth and
“synaptogenesis” which are impaired by and depend on the
asphyxia severity and damaging effects by the post-
asphyxic re-oxygenation [26, 49–54]. Metabolic particu-
larities of the asphyxia/re-oxygenation pathology are
summarised in Fig. 11. Hypoxic-ischaemic encephalopa-
thy [55–57], CNS damage [58, 59], epilepsy [60, 61],
nephropathy [43], cardiomyopathy [62, 63], vascular
pathologies [64], senescence [32, 65], diabetes mellitus
[66, 67], cancer [68], neurodegenerative diseases [58],
morbidity and mortality [69] and tissue remodelling [70]
all belong to individual short- and long-term outcomes of
birth asphyxia. Specialised issue of The EPMA Journal,
further treat the major related topics, namely “PPPM in
Diabetes”, “PPPM in Neurodegenerative Diseases”,
“PPPM in Cancer”, “PPPM in Cardiovascular Diseases”,
“PPPM in Body Culture and Sport Medicine”, “Healthcare
Overview”, where the articles overview the innovative
technologies of predictive diagnostics, targeted prevention
measures and desirable personalisation of medical care
[71–80].
Biomarker-candidates in blood specific for asphyxia
and related complications
Blood tests is a highly attractive approach for performing
non-invasive examinations to accurately diagnose a severity
grade of birth asphyxia and to predict/prognose individual
predispositions to or a progression of secondary complica-
tions in asphyxia affected newborns. Furthermore, the
discovered blood-brain barrier permeability in hypoxic-
EPMA Journal (2011) 2:197–210 203
ischaemic encephalopathy well explains potential correla-
tions in pathology specific molecular profiles between brain
and blood, justifying the high prognostic value of non-
invasive blood examinations [81].
2
mellitus
l
22
 Apoptosis 
Extensive cell 
lost 
Progressive tissue / 
organ degeneration 
 Proliferation of 
damaged cells 
Precancerous 
lesions 
Damage to chrDNA and mtDNA 
Birth 
asphyxia 
Metabolic 
particularities  
Energy depletion 
Acidosis (low pH) 
High lactate levels 
 Free radicals 
High glutamine levels 
+ High exitatory amino 
acids 
 Ca +;  Na+;  K+
 ATP production 
Impairments and tissue 
damage 
Impaired proliferation of 
the nerve domanine 
terminals
Impaired electron-
transport pump 
Impaired release of 
neurotransmitters 
Impaired glycolysis 
Neural damage 
Blood brain barrier 
breakdown 
 Tissue remodelling 
Short- and long-term 
 outcomes 
Morbidity and mortality
Specialised issue 
of The EPMA 
Journal, 2010  
PPPM in 
Neurodegenerative 
Diseases 
Epilepsy 
Neurodegenerative diseases 
Central  Nervous System injuries 
Hypoxic-ischaemic encephalopathy 
Nephropathy
Senescence 
Diabetes 
Specialised issue 
of The EPMA 
Journal, 2010 
Cancer 
Specialised issue of  
The EPMA Journa , 2010
PPPM  
in Cancer 
Vascular 
pathologies 
Cardiomyopathy
Specialised issue 
of The EPMA 
Journal, 2011 
PPPM 
Cardiovascular 
Diseases 
PPPM in Diabetes 
mellitus  
Fig. 11 Metabolic particularities, impairments and individual outcomes by perinatal asphyxia. Abbreviations: mtDNA = mitochondrial DNA;
chrDNA = chromosomal DNA; ATP = adenosine three-phosphate; PPPM = predictive, preventive and personalised medicine
204 EPMA Journal (2011) 2:197–210
In newborn term infants with intra-partum signs of foetal
distress, the blood-plasma levels of lactate-dehydrogenase
are considered as a good predictor of hypoxic-ischaemic
encephalopathy during the first 12 h after birth. This result
is of clinical interest offering a potential inexpensive and
safe prognostic marker in newborn infants with perinatal
asphyxia [82].
The oxidative stress markers as measured in blood, are
well recognised as the good predictors of poor outcomes in
newborns with asphyxic deficits [83].
Acute kidney injury is a common consequence of
perinatal asphyxia, occurring in up to 56% of these infants.
Therefore, the pathology specific biomarkers are of great
clinical value being currently under extensive consideration
by researchers [84].
S100B is considered as one of the most potent blood-
markers, significantly increased in blood serum 24 h after
severe birth asphyxia insult in newborns [85–89].
Our recent studies demonstrated highly increased S100B
expression rates, specifically, in the mesencephalon of the
experimental rats, even 1 month after severe birth asphyxia.
Potentially the brain tissue of the mesencephalon area
overproducing S100B can be also the source of the
increased S100B levels in the blood-serum, due to the
blood-brain-barrier breakdown that is characteristic for
hypoxic-ischalmic encephalopathy. However, the proteins
of S100-family cannot be considered as asphyxia specific
biomarkers, since significantly increased expression levels
of them have been detected in blood of several patient
cohorts, who suffer from different types of pathologies—
neurodegenerative and vascular disorders [90–92], cardio-
myopathy [93], several cancer types [94, 95].
The diagnostic approaches, which utilise pathology-
specific biomarkers, are more promising in predicting an
individual predisposition to pathologies, monitoring a
disease progression and serving as the selective targets for
tailored therapeutic measures. Here we provide some
examples for potential biomarker-candidates discovered in
our recent studies. Hence, a significant elevation of TAU-
protein transcriptional rates has been demonstrated in the
blood of experimental rats with expression peaks specific
for the brain-regions in certain time-frame: 48-h—in
mesencephalon and hypothalamus and 1-week—in telen-
cephalon, as monitored after the severe asphyxic insult (see
Fig. 12).
Moreover, there is an evident correlation between the
expression peaks in individual brain-regions and appear-
ance of the TAU-transcripts in blood of asphyxiated pups.
The up-regulation of the TAU-levels is characteristic for
Alzheimer’s disease and has been implicated in the
pathology-specific molecular mechanisms [97].
Further, the measurements of the HER-2 transcripts in
brain and full blood revealed sufficient differences between
the groups of asphyxiated and normoxic animals as
demonstrated in Fig. 13.
According to the above given results, both TAU-protein
and HER-2 can be considered as biomarker-candidates for
further validating tests in clinical studies.
Outlook: supportive and protective therapeutic
approaches for newborns with asphyxic deficits
Re-oxygenation of newborns with asphyxic deficits triggers
a cascade of compensatory biochemical events to restore
function, which may be accompanied by improper homeo-
stasis and oxidative stress. In the clinical scenario, no
specific treatments have yet been established to protect
asphyxic newborns against hypoxic/re-oxygenation stress.
In the clinical setting, after resuscitation of an infant with
birth asphyxia, the emphasis is on supportive therapy.
Several interventions have been proposed to attenuate
secondary neuronal injuries elicited by asphyxia, including
hypothermia. Hypothermia has been pointed out to be an
effective intervention against the secondary neuronal injury,
elicited by the birth asphyxia [98]. Applied immediately
after birth asphyxia, hypothermia generally lowers meta-
bolic rates, and diminishes the glutamate levels in brain
[98–100]. Although promising, the clinical efficacy of
hypothermia has not been fully demonstrated. It is evident
that new approaches are warranted.
In the context of neuroprotection, several sentinel
proteins have been described to protect the integrity of the
genome (e.g. PARP-1, XRCC1, DNA ligase IIIα, DNA
polymerase β, ERCC2, DNA-dependent protein kinases).
They act by eliciting metabolic cascades leading to (i)
activation of cell survival and neurotrophic pathways; (ii)
early and delayed programmed cell death, and (iii)
promotion of cell proliferation, differentiation, neurito-
genesis and synaptogenesis. It is proposed that sentinel
proteins can be used as markers for characterising long-
term effects of perinatal asphyxia, and as targets for novel
therapeutic development and innovative strategies for
neonatal care [101].
Nicotinic acid and nicotinamide have been proposed to
protect against oxidative stress [102, 103], ischaemic
injury [104] and inflammation [105] by replacing the
depletion of the NADH/NAD+-pair produced by PARP-1,
which is over-activated under severe hypoxic conditions
[106]. Therapeutic application of nicotinamide has been
reported to prevent several of the changes induced by
perinatal asphyxia on monoamines, even if the treatment is
delayed for 24 h, suggesting a clinically relevant thera-
peutic window [107]. Therefore, this approach is currently
considered as the therapeutic strategy against the long-
term deleterious consequences of birth asphyxia as well as
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for several pathophysiologic conditions such as myo-
cardial reperfusion injury, stroke, neurotrauma, arthritis,
multiple sclerosis and severe complications secondary to
Diabetes mellitus [105].
The application of low concentrations of NO-inhibitors
is beneficial against extensive ischaemic lesions in brain
[108]. Pre- and post-hypoxic treatment with NMDA-
receptor antagonists appears to reduce cerebral tissue injury
[109, 110]. Calcium-channel blockers have also been
demonstrated to have beneficial effects [109] by reducing
post-asphyxic lesions in brain.
Pretreatment with barbiturates may improve survival and
reduce the severity of brain injury [109]. It reduces cerebral
metabolism [111] and decreases oxygen consumption [112].
By lowering the oxygen consumption, it prevents free-radical
destruction of the cell membranes [113]. The barbiturate
pretreatment reduces the intra- and extra-cellular accumula-
tion of water and, in this way, prevents convulsions [114].
Postnatal treatments with free-radical scavengers such as
dimethylthiourea, xanthine-oxidase, and allopurind-inhibitor
improve clinical outcomes after perinatal asphyxic insults
[115, 116].
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